# Andrew Wardley

Source: https://onco.cc/people/andrew-wardley/  
OnCo record `andrew-wardley` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.

## Summary

Andrew Wardley is a consultant medical oncologist at The Christie NHS Foundation Trust and Honorary Professor at the University of Manchester. He specialises in breast cancer, HER2-positive disease and adjuvant trials. He contributed to PERSEPHONE, the trial that compared six months with twelve months of adjuvant trastuzumab. His papers include the monarcHER phase 2 trial of abemaciclib plus trastuzumab with or without fulvestrant in hormone receptor-positive, HER2-positive advanced breast cancer, the PERUSE study of first-line pertuzumab with trastuzumab and a taxane, and a study of enzalutamide with trastuzumab in HER2-positive, androgen receptor-positive disease. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Consultant Medical Oncologist, The Christie; Honorary Professor, University of Manchester
- Specialisms: Breast cancer; HER2-positive disease; Adjuvant trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- institutions: [The Christie NHS Foundation Trust](https://onco.cc/institutions/the-christie/)
- trials: [PERSEPHONE](https://onco.cc/trials/persephone/)
- journals: [Breast cancer research and treatment](https://onco.cc/journals/breast-cancer-research-and-treatment/)
- key papers: [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/)

---
JSON: https://onco.cc/api/v1/entities/andrew-wardley.json